Search hospitals > Colorado > Denver
Presbyterian - Saint Lukes Medical Center - Health One
Claim this profileDenver, Colorado 80218
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Lymphoma
Conducts research for Leukemia
360 reported clinical trials
5 medical researchers
Summary
Presbyterian - Saint Lukes Medical Center - Health One is a medical facility located in Denver, Colorado. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Lymphoma, Leukemia and other specialties. Presbyterian - Saint Lukes Medical Center - Health One is involved with conducting 360 clinical trials across 484 conditions. There are 5 research doctors associated with this hospital, such as Nicholas DiBella, Alireza Eghtedar, Peter McSweeney, MD, and Keren Sturtz.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder6 years of reported clinical research
Expert in Breast Cancer
Expert in Lung Cancer
103 reported clinical trials
193 drugs studied
Alireza EghtedarColorado Blood Cancer Institute4 years of reported clinical research
Studies Acute Myelogenous Leukemia
Studies Leukemia
12 reported clinical trials
25 drugs studied
Peter McSweeney, MDColorado Blood Cancer Institute8 years of reported clinical research
Studies Multiple Myeloma
Studies Lymphoma
6 reported clinical trials
9 drugs studied
Keren SturtzSCL Health Lutheran Medical Center10 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
4 reported clinical trials
14 drugs studied
Clinical Trials running at Presbyterian - Saint Lukes Medical Center - Health One
Lung Cancer
Melanoma
Breast Cancer
Bladder Cancer
Cutaneous Melanoma
Breast cancer
Esophageal cancer
Cancer
Lymphoma
Prostate Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Presbyterian - Saint Lukes Medical Center - Health One?
Presbyterian - Saint Lukes Medical Center - Health One is a medical facility located in Denver, Colorado. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Lymphoma, Leukemia and other specialties. Presbyterian - Saint Lukes Medical Center - Health One is involved with conducting 360 clinical trials across 484 conditions. There are 5 research doctors associated with this hospital, such as Nicholas DiBella, Alireza Eghtedar, Peter McSweeney, MD, and Keren Sturtz.
Where is Presbyterian - Saint Lukes Medical Center - Health One located?
**Presbyterian/St. Luke's Medical Center**
- **Address:** 1719 E 19th Ave, Denver, CO 80218
- **Directions:** Accessible via I-25 N, exit 205B for 20th Ave.
- **Hours:** Open 24/7
- **Services Offered:** Emergency care, surgery, women's health, cancer care, orthopedics, cardiology, neurology, and pediatrics.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Presbyterian - Saint Lukes Medical Center - Health One:
- **Pricing Estimates & Prospective Services:** Call (800) 370-1983.
- **Billing Questions:** Refer to the customer service number on your statement.
- **Assistance for Uninsured/Underinsured:** Call 505-841-1406.
For more details, visit the HealthOne Cares and Presbyterian Healthcare Services websites.
What insurance does Presbyterian - Saint Lukes Medical Center - Health One accept?
Presbyterian - Saint Lukes Medical Center - Health One and its affiliated entities, including HealthONE Presbyterian/St.Luke's Medical Center and Saint Luke's Hospital, accept a wide range of insurance plans. These include commercial/group products, Medicare Advantage, managed Medicaid/Centennial Care, Medicaid, Medicare-Denver Boulder, Senior plans, and plans from Aetna, Blue Cross Blue Shield, Cigna, Humana, and United Healthcare. It is recommended to verify insurance coverage with the specific hospital or healthcare provider before receiving services.
What awards or recognition has Presbyterian - Saint Lukes Medical Center - Health One received?
Presbyterian/St. Luke's Medical Center, part of HealthONE in Denver, Colorado, has been named the top large health system by IBM Watson Health for two consecutive years. It ranks as the top hospital in Colorado and #46 in the US for cancer care by U.S. News & World Report in 2023. The hospital is a pioneer in medical advancements, including the first heart transplant in 1985, the first bone marrow transplant in 1991, and introducing robotic surgery to Denver and the surrounding regions in 2003.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.